Topoisomerase I/II-IN-9
Topoisomerase I/II-IN-9 is a topoisomerase I/II inhibitor (IC50<10 μM) and a DNA damage inducer. Topoisomerase I/II-IN-9 blocks the interaction between the enzyme and DNA by binding to the DNA-binding pocket of the enzyme. Topoisomerase I/II-IN-9 activates the cGAS-STING pathway and promotes the accumulation of cytoplasmic double-stranded DNA. This further drives the production of type I interferons, CCL5, CXCL10 and interferon-stimulated genes, and induces anti-tumor immune responses in vivo. Topoisomerase I/II-IN-9 can be applied to the research of related diseases such as triple-negative breast cancer, colorectal cancer and gastric cancer.
For research use only. We do not sell to patients.
- Formula: C35H37F6N3OPRu
- Molecular Weight:761.72
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Topoisomerase I <10 μM (IC50) |
Topoisomerase II <10 μM (IC50) |
Topoisomerase I/II-IN-9 (Ru-4) exhibits potent in vitro antiproliferative activity against CT26, MGC-803, MDA-MB-231, and 4T1 cancer cells, with the highest potency against 4T1 cells (24 h, IC50=1.09 μM)[1].
Topoisomerase I/II-IN-9 (IC50; 48 h) induces DNA double-strand breaks in 4T1 mouse triple negative breast cancer cells[1].
Topoisomerase I/II-IN-9 (IC50; 0-48 h) activates the cGAS-STING-TBK1-IRF3 axis in a time-dependent manner in 4T1 mouse triple negative breast cancer cells, and this activation is required for the induced upregulation of CCL5 and CXCL10[1].
Topoisomerase I/II-IN-9 (IC50; 0-48 h) induces time-dependent upregulation of phosphorylated STAT1 in 4T1 mouse triple negative breast cancer cells, with significant activation observed by 24 h of treatment[1].
Topoisomerase I/II-IN-9 (IC50; 0-48 h) induces time-dependent upregulation of CCL5 and CXCL10 expression and secretion in 4T1 mouse triple negative breast cancer cells, with maximum secretion of ~135 pg/mL CCL5 and ~2400 pg/mL CXCL10 at 48 h[1].
Topoisomerase I/II-IN-9 (1.2-4.8 μM; 48 h; IC50; 0-48 h) upregulates IFN-β and ISG15 mRNA expression in a concentration- and time-dependent manner in 4T1 mouse triple negative breast cancer cells[1].
Topoisomerase I/II-IN-9 (1.2-4.8 μM; 48 h) stimulates concentration-dependent secretion of IFN-β protein in 4T1 mouse triple negative breast cancer cells, with maximum secretion of ~16 U/mL at 4.8 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:4T1 mouse triple negative breast cancer cells
-
Concentration:IC50
-
Incubation Time:48 h
-
Result:Induced a notable increase in γ-H2AX fluorescence intensity compared to untreated controls.
Confirmed the induction of DNA double-strand breaks.
-
Cell Line:4T1 mouse triple negative breast cancer cells
-
Concentration:1.2, 1.8, 2.4, 3.6, 4.8 μM; IC50
-
Incubation Time:48 h (1.2, 1.8, 2.4, 3.6, 4.8 μM); 0, 12, 24, 36, 48 h (IC50)
-
Result:Upregulated IFN-β and ISG15 mRNA levels in a concentration-dependent manner.
Upregulated IFN-β and ISG15 mRNA levels in a time-dependent manner.
Caused statistically significant increases at all tested concentrations and time points relative to untreated controls.
-
Cell Line:4T1 mouse triple negative breast cancer cells
-
Concentration:1.2, 1.8, 2.4, 3.6, 4.8 μM
-
Incubation Time:48 h
-
Result:Increased IFN-β secretion in a concentration-dependent manner.
Caused statistically significant increases at all tested concentrations relative to untreated controls.
Reached a maximum level of ~16 U/mL at 4.8 μM.
Topoisomerase I/II-IN-9 (20 mg/kg; i.v.; every 2 days) exhibits potent in vivo antitumor activity in female BALB/c mice bearing 4T1 tumors, with a 36.7% tumor growth inhibition rate, activates the cGAS-STING pathway, and enhances antitumor immune responses by increasing effector T cell populations and reducing regulatory T cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 4T1 tumor cells implanted when tumor diameter reached 20 mm3)[1]
-
Dosage:20 mg/kg
-
Administration:i.v.; every 2 days
-
Result:Inhibited 4T1 tumor growth with a 36.7% tumor growth inhibition rate, which was higher than the inhibition rates of cisplatin (18.4%) and anti-PD1 (13.9%) alone.
Induced only modest body weight loss, compared to significant weight loss in cisplatin-treated mice.
Upregulated tumor expression of p-STING (7.56-fold increase), p-IRF3 (5.85-fold increase), CXCL10 (5.52-fold increase), and CCL5 (6.98-fold increase) relative to controls.
Increased the percentage of CD3+CD8+ T cells to 2.21%, CD3+CD8+Ki67+ T cells to 55.54%, and CD3+CD8+CD38+ T cells to 46.99%.
Increased the percentage of CD3+CD4+ T cells to 7.42% and CD4+CD185+ (Th) cells to 31.66%.
Reduced tumor CD3+CD4+Foxp3+ (Treg) cells to 2.19%.
Increased expression of TNF-α (5.58%), IFN-γ (10.80%), and GZMB (5.81%) in tumor CD3+CD8+ T cells (from 0.14%, 0.44%, and 0.28% in controls, respectively).
Chemical Information
-
Molecular Weight 761.72
-
Formula C35H37F6N3OPRu
-
SMILES
C[Ru]1([N]2=CC=C(N(C)C)C=C2)[N](C=C3)=C4C5=C(C=CC=C51)C(C6=CC=CC3=C64)=O.CC7=CC=C(C(C)(C)C)C=C7.F[P-](F)(F)(F)(F)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Topoisomerase I/II-IN-9 Related Classifications
HY-182926 Related Classifications
Powered by Bioz